Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical Studies
Teena Chopra, Daniel Van Handel, Brian Baggott, Robert Orenstein, Kelly Reveles, Beth Guthmueller, Shivam Srivastava, Sahil Khanna · 2026
Read Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical Studies by Teena Chopra, Daniel Van Handel, Brian Baggott, Robert Orenstein, Kelly Reveles, Beth Guthmueller, Shivam Srivastava, Sahil Khanna (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13350609.txt.
Description
Teena Chopra and co-authors review efficacy results from seven studies of a live stool based product that prevents repeat Clostridioides difficile infection. The gut infection is among the most common caught in United States care, and standard antibiotics fail to stop its return in up to one third of cases. The product is the first of its kind approved there.
The program enrolled over 1,700 adults across trials, open cohorts, past record studies, and real world data. All had repeat infection and took antibiotics before the product. Most got it rectally, while two studies used a colonoscope route. The review lays out each design and centers on how well treatment worked.
Catalog record
| CREATOR | Teena Chopra, Daniel Van Handel, Brian Baggott, Robert Orenstein, Kelly Reveles, Beth Guthmueller, Shivam Srivastava, Sahil Khanna |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |